Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.01 USD | +1.00% | +8.93% | +6.08% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The stock, which is currently worth 2024 to 0.31 times its sales, is clearly overvalued in comparison with peers.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Managed Healthcare
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+6.08% | 501M | - | ||
-4.33% | 464B | B- | ||
+11.27% | 94.66B | B- | ||
-23.72% | 42.08B | A- | ||
-2.01% | 38.81B | B- | ||
-10.30% | 18.99B | B- | ||
-28.27% | 2.54B | C+ | ||
-13.94% | 1.42B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- CLOV Stock
- Ratings Clover Health Investments, Corp.